Insights into the Spectrum of Activity and Mechanism of Action of MGB-BP-3.

"The authors declare the following competing financial interest(s): ISH, CJS and FJS are part of revenue sharing agreements with their University relating to the Strathclyde Minor Groove Binder project, of which MGB-BP-3 is a part. Additionally, ISH, CJS and FJS have financial interests through shares in the company, Rostra Therapeutics. Notes: I.S.H., C.J.S., and F.J.S. are part of revenue sharing agreements with their University relating to the Strathclyde Minor Groove Binder Project of which MGB-BP-3 is a part. Additionally, I.S.H., C.J.S., and F.J.S. have financial interests through shares in the company, Rostra Therapeutics."

"This work was in part supported by an EPSTC DTP award to the University of Strathclyde, EP/T517938/1 (2432483, 2432472, and 2483482); the Chief Scientist’s Office grants awarded to F.J.S. (COV/SCL/20/01 and TCS/19/33); an RSC summer studentship awarded to F.J.S. and H.J.T. (U21-4554877873); an Analytical Chemistry Trust Fund Fellowship awarded to F.J.S.; a Wellcome Trust Seed Award awarded to F.J.S. (210103/A/18/Z); a UKRI FLF awarded to R.B. (MR/T020970/1); the UKHSA Grant-in-aid funding, Project 111742; and the 800 MHz NMR data were acquired through EPSRC support under Grant Code EP/R030065/1."